The Strongest Candida Killer - Avantamine
- johnny3283
- Apr 4
- 9 min read
Each year, fungal infections affect up to 1 billion people worldwide. While many of these infections are mild, they can become life-threatening, particularly for individuals with weakened immune systems.
Candida auris (C. auris) is a relatively newly identified fungal infection that has been making headlines due to its ability to spread quickly and cause serious infections. What makes C. auris truly unique is its ability to grow at human body temperature and in saline conditions, enabling rapid colonization on the skin of immuno-compromised patients. Colonized patients have up to a 20% chance of developing an invasive infection, and infected patients have a ~40% mortality rate in 30 days.
In response to this growing threat, AvantGuard’s innovative molecule, Avantamine™, is emerging as a potential solution in the fight against C. auris. With its unique properties and broad-spectrum efficacy, Avantamine offers hope for more effective treatment and prevention of this dangerous pathogen.
A Worldwide Threat to Human Health
C. auris was first identified in 2009 and has since become a growing global health concern, with cases reported in 6 continents and over 30 countries. Its rapid spread in healthcare facilities and alarming resistance to treatment led the World Health Organization to classify it as a "Critical Priority" – one of only four fungal strains to receive this designation.
What Is Candida auris?
C. auris is a newly identified yeast species within the Candida family, but unlike many of its relatives, it poses a growing global health threat. Its name is derived from the Latin word "auris," meaning "ear," as it was first identified in Japan in 2009, where it was isolated from a patient's ear.
C. auris can cause a range of infections, from mild skin infections to more severe, life-threatening conditions, such as bloodstream infections. C. auris is often resistant to antifungal drugs and medications, complicating treatment efforts. This resistance allows the yeast to continue to grow and spread, making infections harder to manage and treat.
Candida auris Outbreak
Since its discovery, C. auris has rapidly spread across six continents, particularly in healthcare settings, where it resists treatment and spreads easily through direct contact or contaminated surfaces. C. auris also often coexists with other multidrug-resistant organisms, further complicating treatment. In the U.S., cases have surged by an average of 70% annually since 2019, surpassing 14,000 clinical and colonized cases in 2023. It is now listed as the #1 fungal pathogen on the CDC’s urgent threat list.
Adding to the challenge, C. auris thrives on human skin and can persist on surfaces for extended periods, making it especially difficult to eradicate. It can survive for weeks on bedrails, doorknobs, and medical equipment, yet it spreads to new patients in as little as four hours. Even those who are simply colonized – meaning the fungus is present on their skin without causing an active infection – can unknowingly transmit it to others.
This rapid and silent spread necessitates costly Contact Precautions like patient isolation, which costs up to $158 per day. Without better solutions, these measures alone could cost $5.7 billion by 2028.
Patients with weakened immune systems – such as those undergoing chemotherapy, receiving AIDS treatment, or recovering from organ transplants – face the highest risk of severe infections.
Researchers suspect that widespread antibiotic and antifungal use in healthcare and agriculture has fueled its rise by disrupting microbial balance. Some also believe excessive disinfectant use in medical settings may have played a role. While its exact origins remain unclear, C. auris continues to challenge healthcare systems worldwide, highlighting the urgent need for better prevention and treatment strategies.
Candida auris Symptoms
C. auris infections can affect various parts of the body, including the bloodstream, wounds, and ears. Because its symptoms depend on the site and severity of infection, there is no single defining symptom of C. auris. In many cases, infections present with general signs similar to bacterial infections, such as fever and chills, which can make diagnosis challenging.
Some individuals carry C. auris on their skin or other body sites without showing symptoms, a state known as colonization. While colonized individuals may not feel sick, they can still unknowingly spread the fungus to surfaces, medical equipment, and other patients, increasing the risk of infection in healthcare settings.
The Dangers of Candida auris
Candida auris Diagnosis and Mortality Rate
C. auris is particularly dangerous due to its challenging diagnosis and high mortality rate. Its symptoms are non-specific and easily mistaken for other infections, often delaying proper treatment and increasing the risk of severe illness.
Once C. auris causes an invasive infection, mortality rates can reach up to 60%, especially in immunocompromised patients. Unlike many drug-resistant pathogens that sacrifice certain traits for resistance, C. auris remains highly adaptable, maintaining its ability to spread while developing resistance even during treatment. This resilience makes it especially difficult to control and treat effectively.
Candida auris Resistance
One of the most significant hurdles in treating C. auris infections is its resistance to multiple antifungal drugs and medications. Unlike other Candida species, it often withstands common treatments like fluconazole, amphotericin B, and even echinocandins—the frontline defense against fungal infections.
The exact mechanisms behind this resistance remain unclear, but C. auris has a high mutation rate, allowing it to develop drug-resistant strains rapidly. This makes controlling outbreaks in healthcare settings especially difficult. Researchers are exploring new strategies, including combination therapies and novel antifungal agents like fosmanogepix, which has shown promise against resistant strains.
Candida auris Surface Decontamination Obstacles
The persistence of C. auris on skin and surfaces for weeks or even months makes it a formidable challenge in healthcare environments. It spreads quickly, potentially moving from one colonized patient to another within just four hours.
One reason for its resilience is the robust biofilm it forms – a protective layer that makes it highly resistant to antifungal treatments and difficult to eliminate. C. auris can contaminate medical equipment, hospital surfaces, and even healthcare workers, leading to persistent outbreaks. Infections have been linked to both shared hospital devices and single-patient equipment like catheters and ventilators, further hindering effective management.
Misidentification in clinical labs can delay proper treatment, worsening infections. To control its spread, hospitals and long-term care facilities must enforce strict disinfection protocols, isolate infected patients, and monitor healthcare workers for colonization.
Challenges in De-colonization of Candida auris
Eradicating C. auris from colonized patients remains a complex and unresolved issue. While healthcare facilities can decontaminate environments after outbreaks, once a patient is colonized, they are considered permanently colonized as no de-colonization method currently exists.
The standard practice of daily bathing with chlorhexidine (CHG) proves ineffective for C. auris. Re-colonization is also a concern, as the fungus can linger in the environment, on bedding, mattresses, and other surfaces.
To prevent transmission, colonized patients require Contact Precautions, which involve isolating them in single-patient rooms, along with strict hygiene protocols for healthcare staff, including wearing gowns and gloves, and washing hands thoroughly when entering and leaving the room.
These measures, while necessary, come at a significant cost of up to $158 per day and are not always feasible for all healthcare settings, particularly when isolating large numbers of patients. No current protocols or treatments for de-colonizing C. auris are available, and no alternative solutions are in development at this time.
The Strongest Candida Killer - Avantamine
To tackle the growing threat of C. auris, AvantGuard introduces Avantamine, a broad-spectrum biocide that offers a unique, three-pronged solution for both skin and surfaces. Avantamine is designed to eliminate all pathogens, including C. auris and its biofilms, without the corrosion and irritation associated with other chlorinated products. This innovative approach includes: (1) a liquid body wash for skin, (2) an antifungal ointment for long-term efficacy, and (3) a residual disinfectant to treat surfaces in healthcare environments.
A Better Antiseptic
Avantamine is a powerful, fast-acting antiseptic that outperforms traditional products like alcohol, chlorhexidine, and povidone iodine. It’s safe for skin and fabric, delivering broad-spectrum efficacy with minimal risk of resistance. Unlike chlorine-based biocides such as hypochlorous acid or bleach, Avantamine provides the antimicrobial power of chlorine without irritation or staining. In testing, Avantamine demonstrated 100,000 times the effectiveness of chlorhexidine and 1,000 times that of iodine in killing tough bacterial biofilms, all without causing skin irritation.
A Better Antifungal Treatment
Avantamine also addresses C. auris colonization with its hydrogel ointment, designed for longer contact time and sustained antifungal activity. By treating high-risk areas like the armpits and groin, Avantamine prevents the growth and spread of C. auris. Unlike traditional antifungal treatments that can promote resistance, Avantamine offers a more effective and sustainable solution. In studies, it proved as effective as 2% miconazole and 1% clotrimazole ointments, and a combination of Avantamine liquid and gel was the most successful in fighting fungal infections.
A Better Disinfectant
Avantamine’s versatility extends to surface decontamination, where it works as a residual disinfectant. Similar to bleach in its efficacy, Avantamine avoids the typical drawbacks – skin irritation, fabric discoloration, and corrosion of metals or plastics. When allowed to dry on surfaces, Avantamine continues to provide long-lasting protection, reducing the risk of C. auris re-colonization and breaking the cycle of contamination in healthcare settings.
Avantamine vs Natural Remedies To Kill Candida
As C. auris continues to pose a significant challenge due to its resistance and persistence, there is growing interest in natural remedies like essential oils as potential alternatives.
Oils such as tea tree, niaouli, white thyme, and cajeput have shown promise in inhibiting C. auris growth, with tea tree and white thyme proving the most effective. These oils not only target planktonic cells but also prevent biofilm formation—a major hurdle in treating infections. In fact, white thyme and cajeput have been found to completely eradicate pre-formed biofilms, while tea tree and niaouli significantly reduce them.
Moreover, combining essential oils with traditional antiseptics like chlorhexidine has also been explored. While chlorhexidine is effective, it struggles to fully eliminate C. auris from the skin, especially in the presence of biofilms. Research suggests that adding essential oils such as tea tree and lemongrass to chlorhexidine may enhance its effectiveness, offering a potential strategy to improve antiseptic performance. However, the long-term stability and consistent ability of these combinations to combat biofilm growth and skin colonization remain areas for further research.
Although essential oils show potential, their long-term effectiveness and stability are still under investigation, and fully understanding their potential as a therapeutic alternative is an area of ongoing study.
A Natural Candida Killer
As the search for effective, safe treatments for C. auris continues, Avantamine offers a groundbreaking and natural solution. Unlike traditional approaches, Avantamine is a bio-inspired, broad-spectrum biocide that combines the power of chlorine with innovative chemistry, providing a safe and highly effective alternative in the fight against C. auris and other pathogens.
Our body’s natural defense mechanisms offer valuable insight into the development of Avantamine. When white blood cells combat pathogens, they utilize chlorine—found naturally in salt—and attach it to the amino acid taurine to form a compound known as taurine chloramine. This biocide effectively targets harmful microorganisms, including bacteria, fungi, and viruses. However, taurine chloramine has a limited shelf life and can only function inside the body.
Avantamine mimics this natural process by stabilizing the chlorine compound, creating a stable, non-corrosive version that can be used safely on both skin and surfaces. This stability allows Avantamine to retain the broad-spectrum antimicrobial properties of taurine chloramine, while providing an effective, long-lasting solution to infections like C. auris. With its innovative formulation, Avantamine eliminates pathogens without the risk of antimicrobial resistance, a major concern with conventional treatments.
What further sets Avantamine apart is its ability to harness the power of chlorine, one of the most effective disinfectants known, while avoiding the common issues associated with traditional chlorinated products. Unlike bleach, which can cause corrosion and irritation, Avantamine is gentle enough for use on skin and safe for a wide variety of surfaces. Its stability and potency ensure it remains effective with a three-to-five year shelf life, offering both safety and reliability in pathogen protection. By eliminating pathogens and their biofilms without contributing to antimicrobial resistance, Avantamine provides a comprehensive approach to combating C. auris and other infectious diseases.
Future Outlook
AvantGuard and its proprietary molecule, Avantamine, are at the forefront of transforming the future of antifungal treatments. By addressing the growing threat of C. auris, Avantamine offers a revolutionary approach that not only targets the pathogen but also reduces the risk of antimicrobial resistance, providing more effective and sustainable treatment options. This innovation holds promise for both treating and preventing infections, creating excitement within the medical community.
AvantGuard’s mission to replace topical antibiotics and offer sustainable alternatives is a critical part of this solution. With versatile products like Avantamine – capable of serving as both a treatment and disinfectant – AvantGuard is contributing to a $30 billion market opportunity. Its broad-spectrum efficacy helps protect human health while also eliminating harmful pathogens like C. auris from surfaces, offering a comprehensive approach to tackling this global health challenge.
Comments